Marker Therapeutics Inc (MRKR)

[ShadowHaven59]

The sped up process of recruiting patients and the good results. They say they’re getting. Could this be why blue owl bought 10%?

[learningcurve2020]

Could what be?

[ShadowHaven59]

Could this be why blue owl holdings bought 10% of the company?

[microcapbiotech]

"In the first five months of 2025 alone, the Company enrolled and successfully manufactured product for more patients than in the entire year of 2024."
That IS good, but considering the snails pace of 2024, ain't really saying that much.
"Objective responses were achieved in 7 out of 9 patients (78%), with 4 patients demonstrating complete response (CR; 44.4%) as early as 4 weeks after infusion of MT-601."
That IS also good, any NEW data?

[Buckboard]

Thanks

[learningcurve2020]

Good news for sure. We need a CEO with a record of success. Given what happened to AlloVir and with Marker’s history, trust in Vera is lacking.

>>Objective responses were achieved in 7 out of 9 patients (78%), with 4 patients demonstrating complete response (CR; 44.4%) as early as 4 weeks after infusion of MT-601.

>> Driven by encouraging early clinical data and a shifting competitive landscape, the Company today announced a marked increase in patient enrollment. In the first five months of 2025 alone, the Company enrolled and successfully manufactured product for more patients than in the entire year of 2024. This upward trend reflects growing momentum and is expected to meaningfully expand the magnitude of the clinical data set, which the Company plans to present later this year.

“We believe the incorporation of lymphodepletion was the right strategic decision as demonstrated by our immunomonitoring data. The incorporation of lymphodepletion has led to increased T cell expansion and persistence, which we believe has the potential to further enhance the clinical outcomes we are seeing. We are now enrolling at an increased pace and are well-positioned to generate meaningful data, which we expect to share by the end of this summer,” concluded Dr. Vera.

[jobynimble]

https://www.globenewswire.com/news-release/2025/05/20/3084834/0/en/Marker-Therapeutics-Reports-that-Lymphodepletion-Improves-the-Expansion-and-Persistence-of-Multi-Antigen-Recognizing-T-Cells-in-Patients-with-Lymphoma.html

[jobynimble]

You’re welcome…

[jobynimble]

You’re welcome…

[Buckboard]

Thanks

[microcapbiotech]

Thank You, I'm sure that they will just rehash the same old information for the 10th time, give out no new information, and they still will be nowhere close to full enrollment.

[jobynimble]

https://www.globenewswire.com/news-release/2025/05/19/3083973/0/en/Marker-Therapeutics-to-Spotlight-Multi-Antigen-Recognizing-MAR-T-Cells-in-High-Profile-Panel-on-CAR-T-Cell-Therapies.html

[learningcurve2020]

Well, at least they’re a serious player.

https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-secures-125-billion-capital-blue-owl-and-cpp

[ShadowHaven59]

From what I’ve been reading and researching, they took a 10% passive investment, which states they believe in the company long term. any other opinions out there? I know the company hasn’t been doing well,but I’m trying to take this as a positive sign

[Buckboard]

I know that. My interest in this stock at this point isn't hi enough to do that so I appreciate u doing it. I haven't sold any shares but as i said, that's because i've lost enough on this that if I lose it all from here it doesn't matter. Also PL has not said "Rose" which is my key technical indicator.
8<)

[ShadowHaven59]

10% ownership by blue owl, holdings, and any opinions out there good or bad? Thank you.

[ShadowHaven59]

Thanks

[jobynimble]

It’s easy to look yourself, just do a search with the stock symbol…

https://www.sec.gov/search-filings

[jobynimble]

You’re welcome…

[Buckboard]

Thanks

[Buckboard]

Thanks

[jobynimble]

10-Q and 13G/A filed yesterday…

13G/A: https://www.sec.gov/Archives/edgar/data/1094038/000114036125019283/0001140361-25-019283-index.htm

10-Q: https://www.sec.gov/Archives/edgar/data/1094038/000141057825001342/0001410578-25-001342-index.htm

[ShadowHaven59]

I’m sorry, I found something but I’m not sure if it’s new or old blue owl holdings filed a 13 G stating they own almost 10% of the company my apologies if this is old news

[ShadowHaven59]

Did earnings call come out today? somebody said it did but I can’t find anything.

[learningcurve2020]

Wow the Vera is a real dynamo! 🙄. Hey Phantom, can’t you light a match under his butt?

[jobynimble]

You’re welcome…

[Buckboard]

Thanks

[jobynimble]

Marker Therapeutics, Inc. 2025 Annual Report

https://www.sec.gov/Archives/edgar/data/1094038/000110465925038714/tm2512723d1_ars.pdf

Click link to read, 124 pages…

[ShadowHaven59]

😂 the response was short and simple, second half of the year, so you were spot on

[microcapbiotech]

I can give you what the answer from the company will be now.
We are "on track" based on our "internal objectives" blah blah blah and doing all we can to "optimize shareholder value" yada yada yada. We appreciate your "continued belief and participation" in our company yawn yawn yawn. We have enrolled 2 patients in out Phase 1 trail (like 2 F...ING years ago) and we may or may not give our "valued" shareholders an update in the 2nd half of 2025, or possibly the 1st half of 2026, or perhaps the 2nd half of 2026, but rest assured dear stockholder, we are "on track" to continue to receive our paychecks and benefits and bonuses and perks, but we do Thank You very much for your continued interest in and commitment to our "on track" company, while we apparently do almost absolutely nothing to reach full enrollment as soon as possible, but at least we are "ON TRACK".

[bar1080]

never, Never, NEVER average down a disappointing penny stock. Most are floor-less and can print huge numbers of additional shares in a wink.

[ShadowHaven59]

Yes, thank you for your response. I was just thinking about averaging my cost down. I also sent an email to the company asking if they will be updating the shareholders on the recruitment in the clinical trials, wish me luck if I get a response, I will let you guys know. I also agree it’s very slow.

[microcapbiotech]

I will try to put this as tactfully as possible.
NOT A SNOWBALLS CHANCE IN HELL.
There is absolutely NO EXCUSE for not being at or at least near full enrollment.
They must PROVE something FIRST.
I have seen tortoises move quicker.
I have seen molasses going uphill in the winter move quicker.
I have seen ... you get my point.

[bar1080]

Learnincurve2020: That's a tidy explanation of how many crappy tiny biomeds work, often just to keep outrageously large paychecks coming in for insiders. The meaningless small testing is incessant... sometimes going on for decades, but almost never producing a real profit or shareholder payout.

[bar1080]

No stock scammer has EVER fooled me, especially a crappy microcap bio-med. I only buy megacap blue chips, usually on the NYSE. Glad to see many are now catching on to the obvious warning signs.

I don't own MRKR. Never have. Never will. Read my bio:https://investorshub.advfn.com/boards/profilea.aspx?user=42712

[ShadowHaven59]

Is anybody out there buying more shares? I’m thinking about it thank you.

[learningcurve2020]

…Bonfiglio was also CEO for a while of that whole Techniclone / Peregrine fiasco.

[learningcurve2020]

Yep. Most biotech operations are there just to enrich management and maybe do a little research for BP on the public’s dime, IMO. At least that’s my takeaway as someone in the biotech space for thirty plus years. Maybe one out of fifty actually perform. ( My god, just look what AlloVir did to their shareholders! ). But mostly these execs just jump from ship to ship with a team of pumpers, or in some cases are expert spinners moving through multiple reverse splits. The entire public biotech sector needs to be rethought.

[microcapbiotech]

The therapy had (and still may) have promise, I just can not comprehend how on earth they can be SO RIDICULOUSLY INEPT and SLOW at enrolling patients, it's looks like they care more about their paychecks and perks than they do enrolling patients.
Been in this for 25 years plus and we are in a Phase 1 trial,
OH HAPPY DAYS.

[ATLdoogie]

Glynn Wilson fooled me. John Bonfiglio fooled me. Peter Hoang fooled me. Juan Vera fooled me. Guess I'm just an old fool.

[microcapbiotech]

WE FINALLY MADE IT ! Back to UNDER $1 - Let the good times roll.
If I didn't think management sucked so much at enrolling patients and are full of ..it with their "on track" based on our "internal" BS,
I would buy more at this price ... BUT with the current clowns at the helm ... AIN'T HAPPENING.
Click the green bull emoji and post.

[microcapbiotech]

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference April 7, 2025.
NOW THIS will get the stock price to over $10 (Yawn).

[learningcurve2020]

It is a joke. They have to get acquired by an entity with real cash otherwise it’s just another one of those research for researches sake companies funded by poor unsuspecting retail.

[learningcurve2020]

>>On March 27, 2025, the Company mutually agreed with Cell Ready to terminate the MSA. In connection therewith, the Company entered into a settlement and release agreement with Cell Ready pursuant to which the Company paid Cell Ready approximately $453,000 and the parties provided one another with mutual releases of all claims associated with any and all agreements between Marker and Cell Ready.

[microcapbiotech]

The Company is enrolling additional study participants in the Phase 1 APOLLO trial (sometime before 2036) and expects to report further data in the second half of 2025 (LOL).

[microcapbiotech]

https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-year-end-2024-corporate-and

[learningcurve2020]

>>Additionally, BCM continues to supply us with products as we continue our clinical trials. Furthermore, in anticipation of the commencement of our larger pivotal trial for Lymphoma in 2026, as well as the eventual need for commercial scale production, we intend to evaluate and qualify additional potential third-party manufacturing partners to provide potential multiple sources of clinical and commercial supply. We currently are in discussions with a number of CDMO candidates and anticipate that we will select a partner organization and commence the qualification and technology transfer process later this year.

>> On March 16, 2018, we entered into an exclusive license agreement, or the BCM License Agreement, with BCM, under which we received a worldwide, exclusive license to BCM’s rights in and to certain intellectual property rights, including European patent EP 2470644 (estimated expiration date August 24, 2030), to develop and commercialize MAR-T cell product candidates.

>> Employees

As of December 31, 2024, we had 5 full-time employees: 1 clinical and 4 in administrative support. None of our employees is subject to a collective bargaining agreement. We consider our relationship with our employees to be good.

>> On December 19, 2024, we issued a press release providing an update on the progress and clinical observations from the Phase 1 APOLLO study, with a data cutoff date of September 10, 2024. Our Phase 1 APOLLO study is investigating MT-601, a MAR-T cell product, in patients with lymphoma who have relapsed after anti-CD19 chimeric antigen receptor (CAR) T cell therapy or where anti-CD19 CAR-T cells are not an option. A total of 10 patients have been treated in the study, for which clinical data is currently available for 9 patients from 5 clinical sites across the United States. Study participants showed early objective responses with and without lymphodepletion. However, immunomonitoring data confirmed that lymphodepletion enhanced the expansion and persistence of MAR-T cell clones in vivo.

>> Recent Developments

On December 19, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company issued and sold in a private Placement the following securities: (i) 1,783,805 shares of common stock, (ii) Series B Warrants, or Pre-Funded Warrants, to purchase an aggregate of 3,247,445 shares of common stock in lieu of shares of common stock and (iii) Series A Warrants, or Private Placement Warrants, to purchase an aggregate of 5,031,250 shares of common stock. The purchase price per share of common stock and accompanying Private Placement Warrant to purchase a share of common stock was $3.20, and the purchase price per Pre-Funded Warrant and accompanying Private Placement Warrant to purchase a share of common stock was $3.199. Total gross proceeds from the sale of securities in the Private Placement, before deducting commissions to the placement agent and estimated offering expenses, was approximately $16.1 million, which does not include any proceeds that may be received upon exercise of any warrants issued in the Private Placement. Both the Pre-Funded Warrants and the Private Placement Warrants are not exercisable until the Company obtains shareholder approval. On March 21, 2025, the Company obtained shareholder approval for the exercise of such warrants. The transaction closed on December 23, 2024.

On March 21, 2025, the Company held a Special Meeting of Stockholders (the “Special Meeting”) at which the stockholders approved, in accordance with Nasdaq Listing Rule 5635(d), of the issuance of the shares issuable upon exercise of (i) Series A Warrants to acquire 5,031,250 shares of Common Stock and (ii) Series B Warrants to acquire 3,247,445 shares of Common Stock.

>>Liquidity and Capital Resources

We have not generated any revenues from the sales or licensing of our product candidates since inception and only have limited revenue associated with grants to fund research. We have financed our operations primarily through public and private offerings of our stock and debt including warrants and the exercise thereof, grants, and in 2023 through the cash proceeds received from the Cell Ready transaction.

Based on our lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activities, and cash and cash equivalents as of December 31, 2024, we anticipate that we will be able to fund our operating expenses and capital expenditure requirements into the first quarter of 2026, assuming no additional grant funds are received. We currently plan to raise additional capital

[learningcurve2020]

I know it’s just a Pl but it seems like a game changer? Still just three patient follow ups?

>>Key findings from the APOLLO study include:

? Safety – Infusion of MT-601 was well tolerated in all study participants, with no observation of immune-effector cell associated neurotoxicity syndrome (ICANS) and one reported Grade 1 cytokine release syndrome (CRS). No dose limiting toxicities (DLTs) have been reported to date.
? Efficacy – In the first dose cohort, 7 out of 9 patients achieved objective responses (78%) at first response assessment, with 4 patients demonstrating complete response (CR; 44.4%) (Table 1).
? Time in Follow-Up – Long-term follow-up of 6 to 12 months is currently available for three patients (Table 2).

>>We reported interim data for an ongoing Phase 1/2 clinical trial (TACTOPS) of the MAR-T cell therapy targeting five TAAs for the treatment of pancreatic adenocarcinoma being conducted by BCM. In this trial, we have observed a clinical benefit with 4 of 13 patients (31%) showing objective responses in front-line unresectable or metastatic pancreatic cancer, which correlated with the post-infusion detection of tumor-reactive T cells in patient peripheral blood and within tumor biopsy samples in patients in the tumor-resection arm of the trial. To date, we have not observed any cytokine release syndrome or neurotoxicity in this trial.

In January 2022, the FDA granted orphan drug designation to MT-601 for the treatment of patients with pancreatic cancer. The FDA cleared our IND application for MT-601 in November 2022 to initiate the PANACEA study, a Phase 1 multicenter clinical trial in locally advanced, unresectable or metastatic pancreatic cancer to assess the safety and efficacy of MT-601 in combination with front-line chemotherapy. The PANACEA trial will include a dose escalation portion followed by a dose expansion portion. We recently announced that the Company has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) and a $2 million grant from the NIH Small Business Innovation Research (SBIR) program to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer. With the support of these grants, we will be able to advance MT-601 in pancreatic cancer without affecting our operations in the ongoing study of MT-601 in patients with lymphoma.

>> We were previously awarded grants from the FDA Orphan Products Grant program ($2 million), NIH Small Business Innovation Research (SBIR) program ($2 million) and the Cancer Prevention and Research Institute of Texas (CPRIT, $13 million), to support the Phase 2 clinical trial of MT-401. All funding agencies have agreed to continue their financial support and to shift funds to the MT-401-OTS program.

Off- the-Shelf MT-401 (MT-401-OTS) for the Treatment of AML and MDS:

Marker previously announced that it intends to focus on the advancement of the MT-401-OTS program in patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). MT-401-OTS has the potential to provide treatment to patients in as little as 72 hours. Marker believes that this fast turnaround time would be beneficial for treating patients with rapid cancer progression, such as patients with measurable residual disease (MRD) in the AML setting. In the OTS program, we intend to dose patients using “banked” products based on partially human leukocyte antigen (HLA) matching. The U.S. FDA has cleared our clinical protocol to investigate MT-401-OTS as a treatment in patients with AML. We already established a cellular inventory manufactured from healthy donors, with ongoing efforts to further expand the inventory. At full scale production, we estimate a single donor could provide treatment for approximately 40 patients, and the current stability program indicates that OTS MAR-T cell products are stable for more than a year in liquid nitrogen, which we expect will permit future on-demand availability for broad-scale implementation. We expect to dose the first patient in the second half of 2025, and, if our OTS program shows promising results in the clinic, we intend to expand the OTS platform to other hematological malignancies and solid tumors. With the grant support from the FDA Orphan Products Grant program, NIH Small Business Innovation Research (SBIR) program and the Cancer Prevention and Research Institute of Texas (CPRIT), the Company will be able to advance MT-401-OTS without affecting the investigation of its lead asset, MT-601, in patients with lymphoma.

[jobynimble]

10-K filing out: https://www.sec.gov/Archives/edgar/data/1094038/000141057825000549/mrkr-20241231x10k.htm

[learningcurve2020]

8-K out.

Item 5.07
Submission of Matters to a Vote of Security Holders.
On March 21, 2025, the Company held a Special Meeting of Stockholders (the "Special Meeting"). At the Special Meeting, the stockholders considered one proposal, which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on February 4, 2025. Of the 10,709,005 shares outstanding as of the record date, 4,158,543 shares, or 38.83%, were present virtually or represented by proxy at the Special Meeting. Set forth below are the results of the matter submitted for a vote of stockholders at the Special Meeting.
Proposal 1: Approval, in accordance with Nasdaq Listing Rule 5635(d), of the issuance of the shares issuable upon exercise of (i) Series A Warrants to acquire 5,031,250 shares of Common Stock (the "Private Placement Warrants") and (ii) Series B Warrants to acquire 3,247,445 shares of Common Stock (the "Pre-Funded Warrants").
For Proposal 1, the votes were cast as follows:
Votes